Cancer proton therapy company Mevion Medical Systems revealed on Monday the election of Curt Kienast as its chief operating officer.
With immediate effect, Kienast is responsible for leading the company's end to end processes, scaling development and amplifying operational excellence.
Prior to the promotion, Kienast has served as the company's vice president of global service as well as held many cross-functional roles during his tenure, including leadership roles in quality assurance, engineering and service.
Kienast's innovative approaches to customer service and lean manufacturing have been instrumental in the company's continued growth and success.
Scancell initiates SCOPE trial's iSCIB1+ cohort
Bio-Thera Solutions' BAT8006 phase II Study receives US FDA IND approval
Poseida Therapeutics names new chief medical officer
Biocytogen and ABL Bio collaborate on development of new bispecific antibody-drug conjugates
BioVaxys Technology announces non-brokered private placement
Senhwa Biosciences doses first subject in phase II study of Silmitasertib
Antennova completes first dosing cohort in Phase one study of ATN-031
M8 Pharmaceuticals collaborates with SERB Pharmaceuticals
BerGenBio ASA starts Phase 2a portion of BGBC016 clinical study of bemcentinib
Phanes Therapeutics receives FDA Fast Track designation for PT886